SOURCE: Paragon Financial Limited

Paragon Financial Limited

January 25, 2012 08:20 ET

Boost in Biotech Funding Benefits CEL-SCI and Human Genome Sciences

The Paragon Report Provides Equity Research on CEL-SCI & Human Genome Sciences

NEW YORK, NY--(Marketwire - Jan 25, 2012) - The biotechnology industry has performed well in the early stages of 2012. The iShares NASDAQ Biotechnology Index is presently up nearly eight percent month-on-month as the industry continues to recover nicely from the global economic crisis. According to a recent report from Global Industry Analysts, Inc. (GIA) the improving economic conditions have led to an increase in funding for the biotechnology industry. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on CEL-SCI Corporation (NYSE Amex: CVM) and Human Genome Sciences, Inc. (NASDAQ: HGSI). Access to the full company reports can be found at:

www.paragonreport.com/CVM
www.paragonreport.com/HGSI

GIA predicts the Global Biotechnology Market to Surpass US$320 Billion by 2015, as increased availability of funding for R&D, expanding use of biotechnology in agriculture and medical sciences, and favorable government initiatives are expected to drive growth in the biotechnology industry.

GIA argues that developing markets, especially India and China, will emerge as major agricultural and industrial biotechnology markets owing to rapid increase in population and income levels. "The two countries are emerging as key markets for biotech drugs due to their rich talent pool and low cost of investment," GIA stated in a press release.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

CEL-SCI Corporation researches and develops drugs and vaccines. The company's lead product, Multikine, is under the Phase III clinical trial for the treatment of head and neck cancer. CEL-SCI's announced last month that its net loss available to common shareholders for the fiscal year 2011 was ($26.8) million, or ($0.13) per share, versus an income of $8.9 million, or $0.04 per share for the fiscal 2010 year.

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer